Exane BNP Paribas Downgrades AstraZeneca (AZN) to Neutral
Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.
Exane BNP Paribas downgraded AstraZeneca (NYSE: AZN) from Outperform to Neutral.
Shares of AstraZeneca closed at $33.24 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Allergan to Present New Data from its Anti-Infectives Portfolio at IDWeek 2016 in New Orleans
- Scotia Howard Weil Downgrades Superior Energy Services (SPN) to Outperform
- Myriad’s BRACAnalysis CDx® Test Identifies Patients with Ovarian Cancer Who Would Benefit from Second-Line Maintenance Treatment with Olaparib
Create E-mail Alert Related CategoriesDowngrades
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!